Affinage

MRPL49

Large ribosomal subunit protein mL49 · UniProt Q13405

Length
166 aa
Mass
19.2 kDa
Annotated
2026-06-10
57 papers in source corpus 2 papers cited in narrative 2 extracted findings
Cross-family judge faithfulness: 3/3 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MRPL49 (NOF) is a structural component of the mitochondrial ribosomal large subunit required for normal biogenesis of the oxidative phosphorylation machinery (PMID:40043708). Bi-allelic loss-of-function variants reduce levels of both mitoribosomal subunits—most markedly the large subunit—without disrupting mitoribosomal assembly, and consequently lower the abundance of OXPHOS complexes I and IV, causing combined oxidative phosphorylation deficiency with multisystem disease (PMID:40043708). The gene maps to chromosome 11q13 in a head-to-head configuration with FAU and encodes a small proline-rich protein that is evolutionarily conserved across mammals (PMID:8786148). Beyond its identification as a mitoribosomal large-subunit component and its disease association (PMID:40043708), no further mechanistic detail has been characterized in the available corpus.

Mechanistic history

Synthesis pass · year-by-year structured walk · 2 steps
  1. 1996 Medium

    Before any function was known, the genomic identity and conservation of MRPL49 had to be established; cloning placed it at 11q13 head-to-head with FAU and defined a conserved small proline-rich product, providing the molecular handle for later functional work.

    Evidence cDNA cloning, genomic sequencing, chromosomal mapping, and cross-species homology comparison

    PMID:8786148

    Open questions at the time
    • No molecular function or subcellular localization was assigned at this stage
    • No link to the mitochondrial ribosome was established
    • Functional significance of the FAU-adjacent head-to-head arrangement unresolved
  2. 2025 Medium

    It was unknown whether MRPL49 had a physiological role in mitochondrial translation; patient-derived complexome profiling showed bi-allelic loss reduces mitoribosomal subunit levels and OXPHOS complexes I and IV, establishing it as a structural mitoribosomal large-subunit component required for OXPHOS biogenesis and the cause of combined oxidative phosphorylation deficiency.

    Evidence Complexome profiling and OXPHOS complex quantification in fibroblasts from patients with bi-allelic MRPL49 variants across nine unrelated families; genome sequencing

    PMID:40043708

    Open questions at the time
    • Single-lab study without independent replication of the molecular phenotype
    • Mechanism by which large-subunit loss propagates to reduced small-subunit levels not resolved
    • No structural placement of MRPL49 within the assembled mitoribosome demonstrated

Open questions

Synthesis pass · forward-looking unresolved questions
  • How MRPL49 is incorporated into the mitoribosomal large subunit and the precise step at which its loss limits OXPHOS complex I and IV biogenesis remain undefined.
  • No direct demonstration of binding partners within the mitoribosome
  • No reconstitution or rescue experiment defining the assembly step affected
  • Tissue-specific basis of the multisystem phenotype unexplained

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005198 structural molecule activity 1
Localization
GO:0005739 mitochondrion 1
Pathway
R-HSA-8953854 Metabolism of RNA 1
Complex memberships
mitochondrial ribosome large subunit

Evidence

Reading pass · 2 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2025 Bi-allelic loss-of-function variants in MRPL49 cause combined oxidative phosphorylation deficiency (COXPD). Complexome profiling of patient fibroblasts revealed reduced levels of both small and large mitochondrial ribosomal subunits (with a more pronounced reduction of the large subunit), without evidence of altered mitoribosomal assembly. This results in reduced levels of OXPHOS enzyme complexes I and IV, establishing MRPL49 as a structural component of the mitochondrial ribosomal large subunit required for normal OXPHOS complex biogenesis. Complexome profiling of patient-derived fibroblasts with bi-allelic MRPL49 variants; genome sequencing; measurement of OXPHOS enzyme complex levels American journal of human genetics Medium 40043708
1996 The human NOF (MRPL49) gene was cloned and characterized at chromosome 11q13, adjacent to FAU in a head-to-head configuration. The largest open reading frame encodes a 166 amino acid proline-rich protein with no homology to known genes at the time, and the locus is evolutionarily conserved with >80% identity to mouse and rat orthologs that also map next to the FAU gene. cDNA cloning, genomic sequencing, chromosomal mapping, BLAST homology analysis Genomics Medium 8786148

Source papers

Stage 0 corpus · 57 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2014 N-of-1 (single-patient) trials for statin-related myalgia. Annals of internal medicine 96 24737272
2003 Light stimulates a transducin-independent increase of cytoplasmic Ca2+ and suppression of current in cones from the zebrafish mutant nof. The Journal of neuroscience : the official journal of the Society for Neuroscience 82 12533607
2021 Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome medicine 78 34607609
2007 Identification of a zebrafish cone photoreceptor-specific promoter and genetic rescue of achromatopsia in the nof mutant. Investigative ophthalmology & visual science 72 17251445
2015 PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug safety 56 25989944
2022 Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic acid therapeutics 43 36516128
1991 Purification and characterization of an 82-kD membrane protein as a neurite outgrowth factor binding protein: possible involvement of NOF binding protein in axonal outgrowth in developing retina. The Journal of cell biology 35 1988463
2005 A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 29 16052316
2024 The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nature reviews. Drug discovery 26 39496921
2012 Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. Parkinsonism & related disorders 23 23283428
2024 A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases. Nature communications 21 39532857
2021 Individual Postprandial Glycemic Responses to Diet in n-of-1 Trials: Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR). The Journal of nutrition 21 34255080
2017 Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. Wellcome open research 20 28815218
1990 Characterization of the FB-NOF transposable element of Drosophila melanogaster. Genetics 18 2174013
2017 Lamin A expression in circulating osteoprogenitors as a potential biomarker for frailty: The Nepean Osteoporosis and Frailty (NOF) Study. Experimental gerontology 17 29203402
2024 Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design. Cancer treatment reviews 16 38484408
2022 Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial. eLife 15 35787784
2012 Discovery-based nutritional systems biology: developing N-of-1 nutrigenomic research. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition 14 23798052
2021 The effect of a color tattoo on the local skin redox regulatory network: an N-of-1 study. Free radical research 10 33855906
2016 Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials. Trials 10 27473188
2020 Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations. Pediatric pulmonology 9 32281737
2015 OncoRep: an n-of-1 reporting tool to support genome-guided treatment for breast cancer patients using RNA-sequencing. BMC medical genomics 9 25989980
2016 Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials. Trials 8 26746195
2025 Toward an Extensible Regulatory Framework for N-of-1 to N-of-Few Personalized RNA Therapy Design. Therapeutic innovation & regulatory science 7 40014258
2017 Testing for differentially expressed genetic pathways with single-subject N-of-1 data in the presence of inter-gene correlation. Statistical methods in medical research 7 28552011
2025 Bi-allelic variants in MRPL49 cause variable clinical presentations, including sensorineural hearing loss, leukodystrophy, and ovarian insufficiency. American journal of human genetics 6 40043708
2024 N-of-1 medicine. Singapore medical journal 6 38527301
2016 Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'. Oncology 5 27705967
2013 FB-NOF is a non-autonomous transposable element, expressed in Drosophila melanogaster and present only in the melanogaster group. Gene 5 23685284
1996 Isolation, cDNA, and genomic structure of a conserved gene (NOF) at chromosome 11q13 next to FAU and oriented in the opposite transcriptional orientation. Genomics 5 8786148
2025 Blueprint for clinical N-of-1 strategies with off-label precision treatments in monogenic epilepsies. Orphanet journal of rare diseases 4 40524218
2018 A Pilot Study of Amino Acids in Unresectable Non-Small-Cell Lung Cancer Patients During Chemotherapy: A Randomized Serial N-of-1 Trials Design. Nutrition and cancer 4 30451538
2023 Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials. Contemporary clinical trials communications 3 38144875
2021 Results of a 5-Year N-of-1 Growth Hormone Releasing Hormone Gene Therapy Experiment. Rejuvenation research 3 34841890
2005 An FB-NOF mediated duplication of the white gene is responsible for the zeste1 phenotype in some Drosophila melanogaster unstable strains. Molecular genetics and genomics : MGG 3 16333669
2025 Efficacy and Safety of Photobiomodulation in MELAS: Protocol for a Series of N-of-1 Trials. Journal of clinical medicine 2 40142856
2025 Milasen: The Emerging Era of Patient-Customized N-of-1 Antisense Oligonucleotides as Therapeutic Agents for Genetic Diseases. Methods in molecular biology (Clifton, N.J.) 2 40720011
2025 Hypoxic conditioning in Parkinson's disease: randomized controlled multiple N-of-1 trials. Nature communications 2 41006236
2024 Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes. Transfusion 2 38214417
2024 N-of-1 health optimization: Digital monitoring of biomarker dynamics to gamify adherence to metabolic switching. PNAS nexus 2 38881838
2023 Complete and sustained remission of hypercortisolism with pasireotide treatment of an adrenocorticotropic hormone (ACTH)-secreting thoracic neuroendocrine tumor: an n-of-1 trial. Endocrine journal 2 36697023
2023 The importance of personalization in high altitude protocols for hematologic and metabolic benefits in sports: A multi-dimensional N-of-1 case study. Heliyon 2 38170057
2026 From Genomic Diagnosis to Personalized RNA Medicine: Advances in Next-Generation Sequencing and N-of-1 Antisense Oligonucleotide Therapies for Rare Genetic Diseases. Genes 1 41898852
2024 Biallelic variants in MRPL49 cause variable clinical presentations, including sensorineural hearing loss, leukodystrophy, and ovarian insufficiency. medRxiv : the preprint server for health sciences 1 39417135
2026 Matching hallmarks of cancer complexity with N-of-1 precision oncology. Med (New York, N.Y.) 0 41831434
2026 An n-of-1 gene-directed drug repurposing trial for an ultrarare genetic condition. Epilepsia 0 41999155
2026 From N-of-1 to versatility in propionic acidemia: Antisense oligonucleotide-mediated skipping of a constitutive PCCA pseudoexon. Molecular therapy. Nucleic acids 0 42028575
2026 Enhancing validation of case-control omics signatures through "minimalist" single-subject analysis (N-of-1 trials): proof of concept in sepsis. Journal of the American Medical Informatics Association : JAMIA 0 42093161
2026 Paying for precision: funding approaches for N-of-1 trials of individualized gene targeted therapies. Orphanet journal of rare diseases 0 42169148
2026 Genome integrity, somatic mutation, and the N-of-1 imperative in aging research. Biogerontology 0 42240775
2025 Athlete burnout and biomarkers: An exploratory, longitudinal N-of-1 study. Psychology of sport and exercise 0 40374022
2025 Personalized N-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors. JCO precision oncology 0 40700673
2025 Rethinking p16, p53, and HPV in HNCSCC through lessons from glioblastoma subclonal evolution toward patient-centric N-of-1 single-cell RNA sequencing paradigm. World journal of clinical cases 0 41256339
2025 Potential benefits of l-serine in children with GRIN2B loss-of-function variants: Randomized n-of-1 trials. Molecular genetics and metabolism 0 41265180
2024 Corrigendum to "Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials" [Contemp. Clin. Trials Commun. 36 (2023)/ DOI: 10.1016/j.conctc.2023.101233]. Contemporary clinical trials communications 0 38533474
2023 [Cystic fibrosis - ETI and type 2 N-of-1 trials : the next step]. Revue medicale de Liege 0 37830320
1990 Possible involvement of neurite outgrowth factor (NOF) receptor in axonal outgrowth from developing chick retina. Neuroscience research. Supplement : the official journal of the Japan Neuroscience Society 0 1701872

Missed literature

Know a paper Affinage missed for MRPL49? Flag it for the maintainers and the community.

No submissions yet.